{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:03:45Z","timestamp":1791083025177,"version":"4.1.0"},"reference-count":96,"publisher":"Elsevier","isbn-type":[{"value":"9780128211083","type":"print"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/bs.pbr.2020.05.010","type":"book-chapter","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T17:26:29Z","timestamp":1591982789000},"page":"99-121","source":"Crossref","is-referenced-by-count":21,"title":["Targeting the 5-HT1B\/1D and 5-HT1F receptors for acute migraine treatment"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.pbr.2020.05.010_bb0010","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/archneur.1967.00470230096013","article-title":"Plasma serotonin in migraine and stress","volume":"16","author":"Anthony","year":"1967","journal-title":"Arch. Neurol."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0015","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1186\/s40064-016-2211-8","article-title":"Recent advances in migraine therapy","volume":"5","author":"Antonaci","year":"2016","journal-title":"Springerplus"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0020","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s11916-003-0036-y","article-title":"The trigeminocervical complex and migraine: current concepts and synthesis","volume":"7","author":"Bartsch","year":"2003","journal-title":"Curr. Pain Headache Rep."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0025","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ncl.2008.11.011","article-title":"The epidemiology, burden, and comorbidities of migraine","volume":"27","author":"Bigal","year":"2009","journal-title":"Neurol. Clin."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0030","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1742-1241.2000.tb11905.x","article-title":"A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine","volume":"54","author":"Boureau","year":"2000","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0035","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1177\/0333102419864132","article-title":"Interim results of a prospective, randomized, open-label, phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)","volume":"39","author":"Brandes","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s10194-016-0717-7","article-title":"Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine","volume":"18","author":"Cady","year":"2017","journal-title":"J. Headache Pain"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0045","doi-asserted-by":"crossref","first-page":"12532","DOI":"10.1523\/JNEUROSCI.2887-09.2009","article-title":"Neurons of the dopaminergic\/calcitonin gene-related peptide A11 cell group modulate neuronal firing in the trigeminocervical complex: an electrophysiological and immunohistochemical study","volume":"29","author":"Charbit","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0050","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/sj.bjp.0703587","article-title":"Contractile responses to sumatriptan and ergotamine in the rabbit saphenous vein: effect of selective 5-HT(1F) receptor agonists and PGF(2alpha)","volume":"131","author":"Cohen","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0055","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.annemergmed.2004.07.430","article-title":"Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature","volume":"45","author":"Colman","year":"2005","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0060","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/brain\/88.5.997","article-title":"Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects","volume":"88","author":"Curran","year":"1965","journal-title":"Brain"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0065","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0028-3908(99)00032-5","article-title":"Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis","volume":"38","author":"Cutrer","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0070","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1517\/13543784.8.5.671","article-title":"Rizatriptan: a new 5-HT1B\/1D receptor agonist for the treatment of migraine","volume":"8","author":"Dahlof","year":"1999","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0075","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/00912700022009431","article-title":"Current and emerging second-generation triptans in acute migraine therapy: a comparative review","volume":"40","author":"Deleu","year":"2000","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0080","first-page":"Cd009663","article-title":"Sumatriptan (intranasal route of administration) for acute migraine attacks in adults","volume":"2012","author":"Derry","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0085","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s004150050396","article-title":"Antimigraine drugs","volume":"246","author":"Diener","year":"1999","journal-title":"J. Neurol."},{"issue":"Suppl 18","key":"10.1016\/bs.pbr.2020.05.010_bb0090","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/0333102497017S1803","article-title":"The clinical pharmacokinetics of zolmitriptan","volume":"17","author":"Dixon","year":"1997","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0095","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1526-4610.2004.04078.x","article-title":"Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine","volume":"44","author":"Dodick","year":"2004","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0100","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1526-4610.2005.05031.x","article-title":"Triptan nonresponder studies: implications for clinical practice","volume":"45","author":"Dodick","year":"2005","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0105","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0140-6736(18)30478-1","article-title":"Migraine","volume":"391","author":"Dodick","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0110","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1177\/0333102419859313","article-title":"Sustained responses to lasmiditan: results from post-hoc analyses of two phase 3 randomized clinical trials for acute treatment of migraine","volume":"39","author":"Doty","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0115","unstructured":"Dr. Reddy's Laboratories Limited. 1992. TOSYMRA (Sumatriptan) Nasal Spray, Prescribing Information. [Accessed April 13, 2020]. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/210884s000lbledt.pdf"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0120","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1476-5381.1989.tb11787.x","article-title":"The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs","volume":"96","author":"Feniuk","year":"1989","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0125","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10194-010-0258-4","article-title":"Why pharmacokinetic differences among oral triptans have little clinical importance: a comment","volume":"12","author":"Ferrari","year":"2011","journal-title":"J. Headache Pain"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0130","first-page":"S43","article-title":"Sumatriptan in the treatment of migraine","volume":"43","author":"Ferrari","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0135","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(01)06711-3","article-title":"Oral triptans (serotonin 5-HT(1B\/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials","volume":"358","author":"Ferrari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0140","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1046\/j.1468-2982.2002.00404.x","article-title":"Triptans (serotonin, 5-HT1B\/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials","volume":"22","author":"Ferrari","year":"2002","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0145","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1177\/0333102410375512","article-title":"Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan\u2014a randomised proof-of-concept trial","volume":"30","author":"Ferrari","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0150","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1152\/jn.1995.74.4.1742","article-title":"Dorsal horn projection targets of ON and OFF cells in the rostral ventromedial medulla","volume":"74","author":"Fields","year":"1995","journal-title":"J. Neurophysiol."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0155","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0140-6736(91)90005-A","article-title":"Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan","volume":"338","author":"Friberg","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1046\/j.1526-4610.2003.03006.x","article-title":"Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment","volume":"43","author":"Gallagher","year":"2003","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0165","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"GBD","year":"2017","journal-title":"Lancet"},{"issue":"Pt 3","key":"10.1016\/bs.pbr.2020.05.010_bb0170","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1046\/j.1469-7580.1997.19030367.x","article-title":"The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: a c-fos immunocytochemical study","volume":"190","author":"Goadsby","year":"1997","journal-title":"J. Anat."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0175","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1212\/WNL.54.1.156","article-title":"Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee","volume":"54","author":"Goadsby","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0180","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: a disorder of sensory processing","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiol. Rev."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0185","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/brain\/awz134","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine","volume":"142","author":"Goadsby","year":"2019","journal-title":"Brain"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0190","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S0140-6736(01)06347-4","article-title":"Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial","volume":"358","author":"Goldstein","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0195","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1046\/j.1468-2982.2001.00208.x","article-title":"Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine","volume":"21","author":"Gomez-Mancilla","year":"2001","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0200","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1021\/acs.molpharmaceut.7b00297","article-title":"Dodecylmaltoside modulates bicellular tight junction contacts to promote enhanced permeability","volume":"14","author":"Gradauer","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0205","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1468-2982.2006.01219.x","article-title":"Intravital microscopy on a closed cranial window in mice: a model to study trigeminovascular mechanisms involved in migraine","volume":"26","author":"Gupta","year":"2006","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0210","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0149-2918(00)80068-5","article-title":"Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 study group","volume":"22","author":"Havanka","year":"2000","journal-title":"Clin. Ther."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0215","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0006-8993(01)02567-7","article-title":"Microinjection of carbachol in the lateral hypothalamus produces opposing actions on nociception mediated by alpha(1)- and alpha(2)-adrenoceptors","volume":"911","author":"Holden","year":"2001","journal-title":"Brain Res."},{"issue":"Pt 4","key":"10.1016\/bs.pbr.2020.05.010_bb0220","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1046\/j.1469-7580.1999.19440579.x","article-title":"Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat","volume":"194","author":"Hoskin","year":"1999","journal-title":"J. Anat."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0225","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/0165-6147(91)90630-B","article-title":"Mode of action of the anti-migraine drug sumatriptan","volume":"12","author":"Humphrey","year":"1991","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0230","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/0333102413485658","article-title":"The international classification of headache disorders, 3rd edition (beta version)","volume":"33","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2013","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0235","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1177\/0091270002042012006","article-title":"Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers","volume":"42","author":"Jansat","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0240","author":"Janssen-Ortho, LLC"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0245","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1097\/00001756-199707070-00029","article-title":"5-HT1F receptor agonists inhibit neurogenic dural inflammation in Guinea pigs","volume":"8","author":"Johnson","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0250","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1468-2982.2005.00836.x","article-title":"Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack","volume":"25","author":"Juhasz","year":"2005","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0255","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1212\/WNL.10.2.107","article-title":"Effect of serotonin in migraine patients","volume":"10","author":"Kimball","year":"1960","journal-title":"Neurology"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0260","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1177\/0333102419855080","article-title":"Safety findings from phase 3 lasmiditan studies for acute treatment of migraine: results from SAMURAI and SPARTAN","volume":"39","author":"Krege","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0265","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","article-title":"Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study","volume":"91","author":"Kuca","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0270","first-page":"362","article-title":"Lasmiditan inhibits CGRP release in the mouse trigeminovascular system","volume":"37","author":"Labastida-Ram\u00edrez","year":"2017","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0275","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s10194-018-0881-z","article-title":"Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study","volume":"19","author":"Landy","year":"2018","journal-title":"J. Headache Pain"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1568007043482570","article-title":"5-HT1 receptors","volume":"3","author":"Lanfumey","year":"2004","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0285","author":"Lily Lilly USA"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0290","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1212\/WNL.59.7.1011","article-title":"Features of medication overuse headache following overuse of different acute headache drugs","volume":"59","author":"Limmroth","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0295","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/head.13309","article-title":"DFN-02 (Sumatriptan 10 mg with a permeation enhancer) nasal spray vs placebo in the acute treatment of migraine: a double-blind, placebo-controlled study","volume":"58","author":"Lipton","year":"2018","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0300","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1468-2982.2008.01829.x","article-title":"Brainstem and thalamic projections from a craniovascular sensory nervous centre in the rostral cervical spinal dorsal horn of rats","volume":"29","author":"Liu","year":"2009","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0305","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1161\/01.CIR.98.1.25","article-title":"Coronary side-effect potential of current and prospective antimigraine drugs","volume":"98","author":"MaassenVanDenBrink","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0310","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1212\/WNL.55.10.1524","article-title":"Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels","volume":"55","author":"MaassenVanDenBrink","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0315","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2147\/IJWH.S63444","article-title":"A review of frovatriptan for the treatment of menstrual migraine","volume":"6","author":"MacGregor","year":"2014","journal-title":"Int. J. Womens Health"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0320","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/head.12499","article-title":"The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies","volume":"55","author":"Marmura","year":"2015","journal-title":"Headache"},{"issue":"Suppl. 1","key":"10.1016\/bs.pbr.2020.05.010_bb0325","first-page":"28s","article-title":"Evaluating the triptans","volume":"118","author":"Mathew","year":"2005","journal-title":"Am. J. Med."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0330","author":"Merck & Co. Inc"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0335","series-title":"Physiological Aspects of Clinical Neurology","article-title":"Innervation of intracranial structures: a reappraisal","author":"McNaughton","year":"1977"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0340","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0014-2999(99)00067-9","article-title":"Both 5-HT1B and 5-HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis","volume":"369","author":"Mitsikostas","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0345","first-page":"27","article-title":"Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache","volume":"6","author":"Moore","year":"2012","journal-title":"Patient Prefer. Adherence"},{"issue":"Suppl. 2","key":"10.1016\/bs.pbr.2020.05.010_bb0350","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/head.13582","article-title":"Targeting CGRP and 5-HT1F receptors for the acute therapy of migraine: a literature review","volume":"59","author":"Moreno-Ajona","year":"2019","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0355","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/head.12905","article-title":"A randomized trial comparing the pharmacokinetics, safety, and tolerability of DFN-02, an intranasal sumatriptan spray containing a permeation enhancer, with intranasal and subcutaneous sumatriptan in healthy adults","volume":"56","author":"Munjal","year":"2016","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0360","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s10194-017-0740-3","article-title":"A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine","volume":"18","author":"Munjal","year":"2017","journal-title":"J. Headache Pain"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0365","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/0333102410370873","article-title":"Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan","volume":"30","author":"Nelson","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0370","doi-asserted-by":"crossref","first-page":"14204","DOI":"10.1523\/JNEUROSCI.3285-11.2011","article-title":"Cortical projections of functionally identified thalamic trigeminovascular neurons: implications for migraine headache and its associated symptoms","volume":"31","author":"Noseda","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0375","first-page":"Cd003221","article-title":"Rizatriptan for acute migraine","author":"Oldman","year":"2001","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0380","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s13311-017-0592-1","article-title":"Migraine treatment: current acute medications and their potential mechanisms of action","volume":"15","author":"Ong","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0385","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2165\/00023210-200418150-00009","article-title":"The PROMISE study: PROphylaxis of MIgraine with SEglor (dihydroergotamine mesilate) in French primary care","volume":"18","author":"Pradalier","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0390","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1586\/ern.10.131","article-title":"Almotriptan: a review of 10 years' clinical experience","volume":"10","author":"Pascual","year":"2010","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0395","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archneurpsyc.1940.02280070051003","article-title":"Dural headache and the innervation of the dura mater","volume":"44","author":"Penfield","year":"1940","journal-title":"Arch. Neurol. Psychiatr."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0400","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1046\/j.1468-2982.2003.00525.x","article-title":"5-HT1F receptor agonists in acute migraine treatment: a hypothesis","volume":"23","author":"Ramadan","year":"2003","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0405","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archsurg.1940.01210040002001","article-title":"Experimental studies on headache. Pain sensitive structures of the head and their significance in headache","volume":"41","author":"Ray","year":"1940","journal-title":"Arch. Surg."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0410","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2147\/NDT.S25531","article-title":"Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan","volume":"10","author":"Rizzoli","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0415","doi-asserted-by":"crossref","first-page":"8827","DOI":"10.1523\/JNEUROSCI.0439-13.2013","article-title":"Paraventricular hypothalamic regulation of trigeminovascular mechanisms involved in headaches","volume":"33","author":"Robert","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0420","first-page":"104","article-title":"Lasmiditan and sumatriptan: comparison of in vivo vascular constriction in the dog and in vitro contraction of human arteries","volume":"36","author":"Rubio-Beltr\u00e1n","year":"2016","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0425","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2165\/11209380-000000000-00000","article-title":"Frovatriptan: a review of its use in the acute treatment of migraine","volume":"26","author":"Sanford","year":"2012","journal-title":"CNS Drugs"},{"issue":"Suppl 18","key":"10.1016\/bs.pbr.2020.05.010_bb0430","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0333102497017S1805","article-title":"Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B\/1D agonist: an overview of efficacy","volume":"17","author":"Schoenen","year":"1997","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0435","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000229194","article-title":"Biochemical investigations in headache: increase in the hydroxyindoleacetic acid excretion during migraine attacks","volume":"19","author":"Sicuteri","year":"1961","journal-title":"Int. Arch. Allergy"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0440","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.1526-4610.2003.03034.x","article-title":"Ergotamine and dihydroergotamine: history, pharmacology, and efficacy","volume":"43","author":"Silberstein","year":"2003","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0445","first-page":"Cd003224","article-title":"Eletriptan for acute migraine","author":"Smith","year":"2001","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0450","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/archneur.59.7.1084","article-title":"Mechanisms of action of the 5-HT1B\/1D receptor agonists","volume":"59","author":"Tepper","year":"2002","journal-title":"Arch. Neurol."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0455","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1517\/14740338.2.2.123","article-title":"Safety profile of the triptans","volume":"2","author":"Tepper","year":"2003","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0460","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/head.13544","article-title":"Characterization of dizziness after lasmiditan usage: findings from the SAMURAI and SPARTAN acute migraine treatment randomized trials","volume":"59","author":"Tepper","year":"2019","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0465","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2165\/00003495-200060060-00003","article-title":"Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy","volume":"60","author":"Tfelt-Hansen","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0470","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1212\/WNL.47.2.361","article-title":"A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine","volume":"47","author":"Touchon","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/bs.pbr.2020.05.010_bb0475","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1017\/S0317167100118943","article-title":"Canadian headache society guideline: acute drug therapy for migraine headache","volume":"40","author":"Worthington","year":"2013","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0480","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/BF02423504","article-title":"Stimulation of cranial vessels excites nociceptive neurones in several thalamic nuclei of the cat","volume":"81","author":"Zagami","year":"1990","journal-title":"Exp. Brain Res."},{"key":"10.1016\/bs.pbr.2020.05.010_bb0485","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0304-3940(91)90681-I","article-title":"Craniovascular application of capsaicin activates nociceptive thalamic neurones in the cat","volume":"121","author":"Zagami","year":"1991","journal-title":"Neurosci. Lett."}],"container-title":["Progress in Brain Research","Update on Emerging Treatments for Migraine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079612320300522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079612320300522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T22:04:39Z","timestamp":1758751479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0079612320300522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780128211083"],"references-count":96,"URL":"https:\/\/doi.org\/10.1016\/bs.pbr.2020.05.010","relation":{},"ISSN":["0079-6123"],"issn-type":[{"value":"0079-6123","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}